Disc Medicine Stock Drops Amid FDA Official's Questions on Drug Effectiveness

Disc Medicine (IRON) shares fall 14% after FDA official questions bitopertin's effectiveness for rare blood disorder, though analysts maintain buy ratings and approval pathway optimism.